Company news
Evofem Biosciences, Inc. (OTC:EVFM) news
Evofem Biosciences, Inc. news releases on 6ix. Latest, Aug 14, 2024: Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
Press releases — page 2
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024
August 13, 2024
OTCQB Venture Virtual Investor Conference Presentations Now Available for On-Demand Viewing
August 1, 2024
Watch the Evofem Biosciences, Inc. Presentation at the 8/1/2024 OTCQB Venture Virtual Investor Conference
August 1, 2024
OTCQB Venture Virtual Investor Conference Agenda Announced for August 1st
July 29, 2024
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
July 24, 2024
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
July 22, 2024
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
July 16, 2024
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
June 26, 2024
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter
June 10, 2024
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
May 14, 2024
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
April 17, 2024
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
March 26, 2024
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
March 19, 2024
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
March 6, 2024
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
January 31, 2024
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
January 7, 2024
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
December 17, 2023
EVFM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Evofem Biosciences, Inc. Is Fair to Shareholders
December 11, 2023
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
December 11, 2023
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
November 13, 2023
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
October 23, 2023
Evofem to Participate in the Virtual Investor Ask the CEO Conference
October 12, 2023
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
September 26, 2023
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
September 10, 2023
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
August 21, 2023
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
August 13, 2023
Evofem to Participate in the Virtual Investor Summer Spotlight Series
July 5, 2023
Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023
May 31, 2023
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
May 16, 2023
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update
April 27, 2023
Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary
April 13, 2023
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required
April 11, 2023
Evofem Biosciences Announces Cost Reduction Measures
March 20, 2023
Evofem Biosciences Appoints Interim Chief Financial Officer
March 8, 2023
Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering
February 28, 2023
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi
February 27, 2023
Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value
February 23, 2023
Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)
January 12, 2023
Costco Adds Phexxi® to Member Prescription Program
January 10, 2023
Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women
January 9, 2023
OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022
December 29, 2022
Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women
October 10, 2022
OTC Markets Group Welcomes New OTCQB Companies – October 10
October 10, 2022
Evofem Biosciences Announces Approval of Phexxi in Nigeria
October 6, 2022
Evofem Biosciences Announces Uplisting to OTCQB
October 3, 2022